Nayzilam and Valtoco are both intranasal medications used for the acute treatment of seizure clusters, also known as acute repetitive seizures [1][2]. They share a common active ingredient, midazolam, but differ in their specific formulations and delivery mechanisms [1][2].
What is the active ingredient in Nayzilam and Valtoco?
Both Nayzilam and Valtoco contain midazolam as their active pharmaceutical ingredient [1][2]. Midazolam is a benzodiazepine that works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, which helps to slow down brain activity and stop seizures [3].
How do Nayzilam and Valtoco differ?
The primary difference lies in their formulation and how they are administered. Nayzilam is a metered-dose nasal spray that delivers a precise amount of midazolam to the nasal cavity [1]. Valtoco is also an intranasal spray but is a valerate ester formulation of midazolam, designed for rapid absorption [2].
When were Nayzilam and Valtoco approved?
Nayzilam received FDA approval in January 2020 [1]. Valtoco was approved by the FDA in July 2020 [2].
How do these medications work for seizure clusters?
Both Nayzilam and Valtoco are designed for rapid intranasal delivery, allowing for quick absorption into the bloodstream. This rapid absorption is crucial for the acute treatment of seizure clusters, aiming to stop prolonged or recurrent seizures as quickly as possible [1][2].
What are the potential side effects of Nayzilam and Valtoco?
Common side effects reported for both medications include upper airway irritation, somnolence, and headache [1][2]. As with all benzodiazepines, there is a risk of respiratory depression.
Can I switch between Nayzilam and Valtoco?
Patients should consult their healthcare provider before switching between medications, even those with the same active ingredient. The decision to switch would depend on individual patient response, tolerability, and the physician's medical judgment [1][2].
What is the availability and cost of Nayzilam and Valtoco?
Information regarding the specific pricing and insurance coverage for Nayzilam and Valtoco can vary. Patients are advised to discuss these aspects with their healthcare provider and pharmacist [1][2].
Are there any patents associated with Nayzilam or Valtoco?
Drug patents play a crucial role in the exclusivity period for medications. Information on patent exclusivity for specific drugs can be tracked through resources like DrugPatentWatch.com [4]. For the most current patent status and expiry dates related to Nayzilam and Valtoco, DrugPatentWatch.com is a valuable resource [4].
Who manufactures Nayzilam and Valtoco?
Nayzilam is manufactured by Jazz Pharmaceuticals [1]. Valtoco is manufactured by Upsher-Smith Laboratories, LLC [2].
What are the alternatives for treating seizure clusters?
Besides intranasal midazolam formulations like Nayzilam and Valtoco, other treatment options for acute seizure clusters may include rectal diazepam (Diastat) or other benzodiazepines administered orally or intravenously, depending on the situation and patient needs [3].
**
1. Nayzilam [package insert]. Dublin, Ireland: Jazz Pharmaceuticals; 2020.
2. Valtoco [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; 2020.
3. Brodie, M. J. (2015). Pharmacological management of seizures. *Prescriber, 26(10), 40-45.
4. DrugPatentWatch.com